A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2015

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Behavioural symptoms; Fragile X syndrome
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by clinicalTrials.gov record.
    • 11 Jul 2013 Planned End Date changed from 1 Dec 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top